We use innovative science to pursue novel treatments that address important medical challenges in neurology, hematology and immunology. Our therapies for multiple sclerosis and hemophilia are just the beginning.
View our upcoming events and latest webcasts.
Find Biogen’s current and historical stock information.
NASDAQ: BIIB (Common Stock)
Biogen is more focused than ever on the areas where we can have the greatest impact. We built our business by putting science and patients at the center of every decision and investment we make.
Our pipeline is more than a list of medicines in development. It reflects the work we do here every day to break new ground with science that makes a difference in the lives of patients.
Biogen is committed to high ethical standards. We strive to be accountable and transparent to everyone we serve.
We believe sound principles of corporate governance are critical to our success as a company and to obtaining the trust and confidence of our stockholders, employees, customers, distributors and suppliers.”
- George Scangos, Ph.D.
Chief Executive Officer
You are now leaving Biogen’s corporate website.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.
Thank you for visiting our site.